ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Intravacc Completes Project for Provention Bio’s Vax Candidate
January 20, 2021Contract development and manufacturing organization (CDMO) Intravacc, said that a candidate polyvalent inactivated coxsackievirus B (CVB) vaccine it developed and manufactured for Provention Bio in less than 36 months, has entered into a first in ... -
Provention Bio Initiates First-in-Human Study of Coxsackievirus B Vaccine Candidate PRV-101
January 06, 2021Provention Bio announced the initiation of PROVENT (PROtocol for coxsackievirus VaccinE in healthy voluNTeers), a first-in-human study of its polyvalent inactivated coxsackievirus B (CVB) vaccine candidate, PRV-101.
Pharma Sources Insight January 2025
